Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 4/20 | 0.39 |
| ▸ | TERT | O14746 | 3/20 | 0.39 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.39 |
| ▸ | PPARG | P37231 | 3/20 | 0.39 |
| ▸ | PPARD | Q03181 | 3/20 | 0.39 |
| ▸ | PPARA | Q07869 | 3/20 | 0.39 |
| ▸ | MAPT | P10636 | 3/20 | 0.39 |
| ▸ | BLM | P54132 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | FABP4 | P15090 | 2/20 | 0.39 |
| ▸ | F7 | P08709 | 2/20 | 0.39 |
| ▸ | F3 | P13726 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | APEX1 | P27695 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12501476 | 1.00 | ALDH1A1 (0.41) | ALDH1A1CYP2D6SMN1; SMN2FAAHTERT | |
| SCHEMBL20529758 | 0.88 | PPARG (0.55) | ALDH1A1FAAHTERTPTPN1PPARG | |
| SCHEMBL20529739 | 0.88 | F7 (0.55) | ALDH1A1FAAHTERTPTPN1PPARG | |
| SCHEMBL20529741 | 0.88 | F7 (0.55) | ALDH1A1FAAHTERTPTPN1PPARG | |
| SCHEMBL7647197 | 0.88 | PPARG (0.55) | ALDH1A1FAAHTERTPTPN1PPARG | |
| SCHEMBL20529764 | 0.86 | TERT (0.58) | FAAHTERTPTPN1PPARGPPARD | |
| SCHEMBL5598319 | 0.86 | TERT (0.58) | FAAHTERTPTPN1PPARGPPARD | |
| SCHEMBL7575667 | 0.86 | TERT (0.58) | FAAHTERTPTPN1PPARGPPARD | |
| SCHEMBL7575671 | 0.86 | TERT (0.58) | FAAHTERTPTPN1PPARGPPARD | |
| SCHEMBL18640772 | 0.86 | TERT (0.58) | FAAHTERTPTPN1PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4519300-A1 | SHORT APOLIPOPROTEIN E MIMETIC PEPTIDES AND METHODS OF USE | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2025-03-12 | — | — | EP | claimed |
| WO-2023215838-A1 | SHORT APOLIPOPROTEIN E MIMETIC PEPTIDES AND METHODS OF USE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2023-11-09 | — | — | WO | claimed |
| CN-116789744-A | Stapling peptide analogue of opioid/neuropeptide FF receptor multi-target molecule DN-9, preparation and application thereof | 兰州大学 | 2023-09-22 | — | — | CN | claimed |
| CN-115811984-A | Antiviral structurally stable SARS-CoV-2 peptides and uses thereof | 丹娜法伯癌症研究院 | 2023-03-17 | — | — | CN | claimed |
| EP-3962933-A1 | SELECTIVE TARGETING OF UBIQUITIN- AND UBIQUITIN-LIKE E1-ACTIVATING ENZYMES BY STRUCTURALLY-STABILIZED PEPTIDES | Dana-Farber Cancer Institute, Inc. (US) | 2022-03-09 | — | — | EP | claimed |
| EP-3737404-A1 | SELECTIVE TARGETING OF APOPTOSIS PROTEINS BY STRUCTURALLY-STABILIZED AND/OR CYSTEINE-REACTIVE NOXA PEPTIDES | Dana Farber Cancer Institute, Inc. (US) | 2020-11-18 | — | — | EP | claimed |
| WO-2020215005-A1 | SELECTIVE TARGETING OF UBIQUITIN- AND UBIQUITIN-LIKE E1-ACTIVATING ENZYMES BY STRUCTURALLY-STABILIZED PEPTIDES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-10-22 | — | — | WO | claimed |
| WO-2019118719-A1 | SELECTIVE TARGETING OF APOPTOSIS PROTEINS BY STRUCTURALLY-STABILIZED AND/OR CYSTEINE-REACTIVE NOXA PEPTIDES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-06-20 | — | — | WO | claimed |
| US-12600757-B2 | Peptides inhibiting gamma-c-cytokine activity and methods of use | Bioniz Therapeutics, Inc. (US) | 2026-04-14 | — | — | US | disclosed |
| EP-4519300-A1 | SHORT APOLIPOPROTEIN E MIMETIC PEPTIDES AND METHODS OF USE | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2025-03-12 | — | — | EP | disclosed |
| EP-4518900-A1 | EBOLAVIRUS SURFACE GLYCOPROTEIN PEPTIDES, CONJUGATES, AND USES THEREOF | Dana-Farber Cancer Institute, Inc. (US) | 2025-03-12 | — | — | EP | disclosed |
| CN-119233984-A | Short apolipoprotein E mimetic peptides and methods of use thereof | 美国政府(由卫生和人类服务部的部长所代表) | 2024-12-31 | — | — | CN | disclosed |
| EP-4359432-A2 | SHORT APOC-II MIMETIC PEPTIDES AND METHODS OF USE | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2024-05-01 | — | — | EP | disclosed |
| US-20240083949-A1 | CELL PENETRATING PEPTIDE COMPOSITIONS AND METHODS THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2024-03-14 | — | — | US | disclosed |
| EP-3606940-A1 | STABLE MODULATORS OF GAMMA-C-CYTOKINE ACTIVITY | Bioniz, LLC (US) | 2020-02-12 | — | — | EP | disclosed |
| WO-2019157131-A1 | CELL-PERMEABLE STAPLED PEPTIDE MODULES FOR CELLULAR DELIVERY | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-08-15 | — | — | WO | disclosed |
| WO-2019118719-A1 | SELECTIVE TARGETING OF APOPTOSIS PROTEINS BY STRUCTURALLY-STABILIZED AND/OR CYSTEINE-REACTIVE NOXA PEPTIDES | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-06-20 | — | — | WO | disclosed |
| WO-2018187499-A1 | STABLE MODULATORS OF GAMMA-C-CYTOKINE ACTIVITY | BIONIZ, LLC (US) | 2018-10-11 | — | — | WO | disclosed |
| US-20140050778-A1 | NUCLEIC ACID BINDING COMPOUNDS, METHODS OF MAKING, AND USE THEREOF | UNIVERSITY OF ROCHESTER (US) | 2014-02-20 | — | — | US | disclosed |
| WO-2012092367-A1 | NUCLEIC ACID BINDING COMPOUNDS, METHODS OF MAKING, AND USE THEREOF | UNIVERSITY OF ROCHESTER (US) | 2012-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083949-A1 | CELL PENETRATING PEPTIDE COMPOSITIONS AND METHODS THEREOF | VIP, IAPP, ANXA5 | ALDH1A1 4823/4885CYP2D6 4791/4885SMN1; SMN2 1286/4885 |
| US-20140050778-A1 | NUCLEIC ACID BINDING COMPOUNDS, METHODS OF MAKING, AND USE THEREOF | NSUN3, NSUN2, HNRNPF | ALDH1A1 1547/4885CYP2D6 3952/4885SMN1; SMN2 1398/4885 |
| US-12600757-B2 | Peptides inhibiting gamma-c-cytokine activity and methods of use | IL15, IL2, IL15RA | ALDH1A1 3007/4885CYP2D6 4160/4885SMN1; SMN2 606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.